Role of Lipid Peroxidation and Antioxidant Enzymes in Omega 3 Fatty Acids Induced Suppression of Breast Cancer Xenograft Growth in Mice by Hardman, W. Elaine et al.
Marshall University
Marshall Digital Scholar
Biochemistry and Microbiology Faculty Research
7-17-2002
Role of Lipid Peroxidation and Antioxidant
Enzymes in Omega 3 Fatty Acids Induced
Suppression of Breast Cancer Xenograft Growth in
Mice
W. Elaine Hardman
Marshall University, hardmanw@marshall.edu
Jesus Munoz Jr.
Ivan L. Cameron
Follow this and additional works at: http://mds.marshall.edu/sm_bm
Part of the Biochemical Phenomena, Metabolism, and Nutrition Commons, Medical
Biochemistry Commons, and the Oncology Commons
This Article is brought to you for free and open access by the Faculty Research at Marshall Digital Scholar. It has been accepted for inclusion in
Biochemistry and Microbiology by an authorized administrator of Marshall Digital Scholar. For more information, please contact
zhangj@marshall.edu.
Recommended Citation
Hardman WE, Munoz J, Cameron IL: Role of lipid peroxidation and antioxidant enzymes in omega-3 fatty acids induced suppression
of breast cancer xenograft growth in mice. Cancer Cell Int 2002, 2:10.
BioMed Central
C
TIONALINTERNA
ANCER CELL
Page 1 of 9
(page number not for citation purposes)
Cancer Cell International
Cancer Cell International 2002, 2 xPrimary research
Role of lipid peroxidation and antioxidant enzymes in omega 3 fatty 
acids induced suppression of breast cancer xenograft growth in 
mice
W Elaine Hardman*1, Jesus Munoz Jr2 and Ivan L Cameron2
Address: 1Pennington Biomedical Research Center, Louisiana State University, 6400 Perkins Road, Baton Rouge LA 70808, USA and 2The 
University of Texas Health Science Center at San Antonio, Dept of Cellular and Structural Biology, 7703 Floyd Curl Dr., USA, San Antonio, TX 
78229-3900, USA
E-mail: W Elaine Hardman* - hardmawe@pbrc.edu; Jesus Munoz - cameron@uthscsa.edu; Ivan L Cameron - cameron@uthscsa.edu
*Corresponding author
Abstract
Background: Supplementing mice with high levels of dietary n-3 polyunsaturated fatty acids
(PUFAs) increases the n-3 PUFAs in cell membranes, increases the susceptibility of the cells for lipid
peroxidation (LPO) and decreases the growth rate of mammary and other tumors. However, the
results of an earlier study indicated that a factor in addition to LPO was involved in the reduction
in tumor growth in n-3 PUFAs fed mice. Athymic mice bearing MDA-MB-231 human breast
carcinoma xenografts, were fed fish oil concentrate (FOC) or control diets, with and without
supplemental Vitamin E (2000 IU /kg diet) and were sacrificed both before and after doxorubicin
(DOX) treatment to evaluate factors involved in tumor growth suppression.
Results: Prior to DOX, basal LPO in the tumor of 3% FOC fed mice was slightly higher than in
the control fed mice and was decreased in mice consuming FOC with vitamin E. Vitamin E
suppressed the DOX induced increase in LPO in the tumors of control mice, however, vitamin E
was not sufficient to suppress a DOX induced increase in LPO in the tumors of FOC fed mice. The
mean growth rate of tumors of FOC fed mice was significantly less than the mean growth rate of
the tumors of control mice. Multiple regression analyses indicated that suppression of glutathione
peroxidase (GPX) activity by FOC prior to DOX therapy was more important than increased LPO
as an explanation of tumor growth suppression. Tumor induced cachexia was decreased in mice
consuming FOC.
Conclusions: It appears that the increased sensitivity to DOX was related to an FOC induced
reduction in GPX activity. FOC reduced tumor induced cachexia.
Background
The results of cell culture and animal studies have shown
that omega 3 polyunsaturated fatty acids (n-3 PUFAs) se-
lectively killed cancer cells in vitro [1]. Furthermore, n-3
PUFAs incorporated into animal diets have reduced tu-
mor growth rates in vivo [2–4]. The prevailing hypothesis
for the reduction in tumor cell growth, in vitro or in vivo,
by supplementing the diet with high levels of n-3 PUFAs
has been that the incorporation of n-3 PUFAs into cell
membranes of the tumor cells increased the susceptibility
of the cells for lipid peroxidation and that the products of
lipid peroxidation subsequently accumulated to cytostatic
or cytotoxic levels [2,5–7]. It has also been reported that
supplementing the diet of cancer xenograft bearing mice
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with n-3 PUFAs could increase the efficacy of edelfosine
[8], doxorubicin [9], mitomycin [10], cyclophosphomide
and 5-fluorouracil [11] or irinotecan [12] against the tu-
mor. Since causing oxidative damage is one of the mecha-
nisms of action of many of these drugs [13], the increased
efficacy of the drug has been attributed to increasing the
susceptibility of tumor cell membranes to lipid peroxida-
tion.
However, the results of one of our early studies indicated
that some factor in addition to lipid peroxidation was in-
volved in the reduction in xenograft growth in fish oil fed
mice [8]. A clue as to this factor(s) was found in the report
by Vankatraman et al. that antioxidant enzyme activity in
the liver was altered following long term consumption of
n-3 PUFAs [14]. We reasoned that alteration of antioxi-
dant enzyme activity in the tumor by consumption of n-3
PUFAs prior to chemotherapy treatment could increase
oxidative stress within the tumor, perhaps resulting an en-
hanced sensitivity to oxidative stress induced by doxoru-
bicin (DOX).
In this study, we wanted to test the hypothesis that there
are changes in the breast cancer xenografts of FOC fed
mice that sensitize the tumor to oxidative stress. MDA-MB
231 human breast cancer bearing athymic mice were fed
fish oil concentrate (FOC) or control diets, with and with-
out supplemental vitamin E and were euthanized both be-
fore and after DOX treatment to test this hypothesis. DOX
was used to induce oxidative stress, supplemental vitamin
E was used to quench oxidative stress. An important as-
pect of the present study was that the n-3 PUFAs dietary
supplement be fed to mice at a level that humans could
readily consume. This level was based on calculation of
calories contributed by the oil as a fraction of the total ca-
loric content of the diet. A product containing more than
65% omega 3 ethyl esters was used to increase the amount
of long chain n-3 PUFAs contained in a small quantity of
the n-3 PUFAs supplement. A high amount of -tocophe-
rol, (vitamin E, 2000 IU/kg diet) was added to the diet of
some mice to suppress lipid peroxidation in tissues.
Results
Fatty acid composition
The fatty acid compositions of the microsomal and mito-
chondrial membrane fractions of liver, colon and MDA-
MB 231 human breast tumor were analyzed by gas chro-
matography. The individual percent compositions for -
linolenic, eicosapentaenoic and docosahexaenoic acids
were summed to estimate the fraction of n-3 fatty acids.
The individual percent compositions for linoleic and ara-
chidonic acids were summed to estimate the fraction of n-
6 fatty acids. The ratios of the n-3 to n-6 fatty acids in each
tissue and subcellular fraction were subjected to statistical
analyses. A two way ANOVA revealed that the n-3 to n-6
ratio (Table 1) was significantly higher in mice that con-
sumed FOC than in mice that consumed corn oil (CO) in-
dicating that n-3 fatty acids were incorporated in cellular
membranes when FOC was provided in the diet of the di-
et. Supplemental Vitamin E in the diet did not effect the
ratio of n-3 to n-6 fatty acids.
Antioxidant enzyme activity
To determine the effect of consumption of FOC on endog-
enous antioxidant enzyme activity, the activities of super-
oxide dismutase (SOD), catalase (CAT) and glutathione
peroxidase (GPX) were determined in the liver, colon and
tumor of mice that had consumed the diet for two weeks.
As summarized in Table 2, two way ANOVA revealed that
the activities of SOD, CAT and GPX were not significantly
altered in the liver or colon due to the consumption of
FOC or of supplemental Vitamin E for two weeks. Howev-
er, GPX activity was significantly less in the tumors of
mice that consumed FOC than in the tumors of mice that
consumed CO and supplemental Vitamin E did not signif-
icantly alter GPX activity. Thus, the effect of consumption
of FOC on GPX activity was different in the tumor than in
the normal host liver or colon.
Lipid peroxidation
Lipid peroxidation was assayed in the livers, colons and
tumors of mice sacrificed after two weeks consumption of
each diet and after two weeks consumption of the diets
and a single injection of DOX 24 h before sacrifice (Table
3). Three way, two way and one way ANOVA revealed that
in the:
1) liver and colon
a) Lipid peroxidation was slightly suppressed by the addi-
tion of vitamin E to either diet, b) DOX treatment did not
significantly increase lipid peroxidation.
2) tumor
a) Supplemental vitamin E prevented an FOC induced in-
crease in basal lipid peroxidation, b) supplemental vita-
min E prevented the DOX induced increase in lipid
peroxidation in mice that consumed the corn oil diet but
did NOT prevent a DOX induced increase in lipid peroxi-
dation in mice that consumed the FOC diet.
Tumor growth rates
Figure 1 illustrates the mean growth rates of the tumors of
each dietary group following DOX treatment. ANOVA re-
vealed that the growth rates of the tumors of both groups
that consumed FOC were significantly less than the mean
growth rates of both of the groups of mice that consumed
either CO diet.
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Figure 1
Tumor growth after initiation of DOX treatment (see methods for dose and diets). Day 0 on the graph was the day of the first
DOX injection. The mean  SE of the slope of each group (n = 4–8 per group) is indicated. One-way ANOVA followed by an
SNK multiple comparison test indicated that the slopes (tumor growth rates in mm3/day) of groups which do not share a
superscript were significantly (p < 0.05) different.
Table 1: The ratio of n-3 to n-6 fatty acids in the microsomal or mitochondrial membranes of liver, colon or tumor in mice fed a diet 
containing either 5% corn oil (CO) or 3% fish oil concentrate (FOC) and 2% CO with or without 2000 IU/kg Vitamin E for two weeks. 
Two way ANOVA revealed that consumption of supplemental Vitamin E did not effect the fatty acid composition thus ratios due to 
dietary fat are shown. Mean  SEM, (n).
Tissue Fraction 5% CO 3% FOC/2% COa Fold difference
Liver Microsomal 0.06  0.02 (8) 1.11  0.18 (7) 18.5
Mitochondrial 0.09  0.02 (8) 0.77  0.08 (7) 8.6
Colon Microsomal 0.18  0.09 (8) 0.62  0.15 (7) 3.4
Mitochondrial 0.24  0.09 (8) 0.59  0.24 (7) 2.5
Tumor Microsomal 0.11  0.10 (8) 1.15  0.10 (7) 10.5
Mitochondrial 0.59  0.57 (8) 1.32  0.37 (7) 2.2
a The n-3 to n-6 ratio was significantly higher in every tissue fraction of mice that consumed the FOC diet than in mice that consumed the CO diet.
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Table 2: Activities (mean + SE) of superoxide dismutase (SOD, units/mg protein), catalase (CAT, mol H2O2decomposed/min/mg pro-
tein) and glutathione peroxidase (GPX, mol -NADP oxidized/g protein) in the tumors, livers and colon of groups of mice fed diets 
containing either 5% CO or 3% FOC and 2% CO with or without 2000 IU Vitamin E/kg diet for two weeks.
Diet type n SOD GPX CAT
Tumor
5% CO 3 10.0  3.2 131  24a 20  6
5% CO + E 3 17.4  7.2 118  17a 40  17
3% FOC 4 9.0  2.3 60  23a 28  7
3% FOC + E 3 14.1  1.9 13  9b 30  10
Liver
5% CO 3 214  44 358  36 531  28
5% CO + E 3 159  16 301  65 535 12
3% FOC 4 156  39 308  73 579  22
3% FOC + E 3 87  10 331  96 587  67
Colon
5% CO 3 4.8  0.4 325  59 28  13
5% CO + E 3 11.5  1.5 220  38 35  14
3% FOC 4 2.2  0.6 172  53 21  5
3% FOC + E 3 10.5  3.6 199  42 33  9
a One way ANOVA followed by an SNK multiple comparison test indicated that the mean GPX in the tumors of groups that share a superscript 
were not significantly different (p < 0.05). There were no other significant differences.
Table 3: Thiobarbituric acid reactive substances (TBARS, nmols/mg protein, mean  SE) in the tumors, livers and colons of groups of 
mice fed diets containing either 5% CO or 3% FOC and 2% CO with or without 2000 IU Vitamin E/kg diet for two weeks. Some mice 
were sacrificed 24 h after one injection of DOX (5 mg/kg body weight, i.v.).
Diet type n TBARS before DOX n TBARS after DOX
Tumor
5% CO 4 0.59  0.30cd 3 0.79  0.12cd
5% CO + E 5 0.53  0.05cd 4 0.59  0.21cd
3% FOC 4 1.09  0.14bc 3 1.46  0.29b
3% FOC + E 3 0.38  0.15d 4 2.37  0.37a
Liver
5% CO 4 1.09  0.38b 3 0.98  0.06b
5% CO + E 5 0.69  0.10b 5 0.71  0.09b
3% FOC 4 1.77  0.19a 4 1.99  0.31a
3% FOC + E 3 0.61  0.08b 4 0.60  0.08b
Colon
5% CO 3 2.58  0.47a 3 1.21  0.57a
5% CO + E 4 2.10  1.72a 5 1.00  0.48a
3% FOC 4 3.40  1.13a 4 2.59  1.01a
3% FOC + E 3 2.27  1.22a 5 2.35  0.77a
a,b,c,d One way ANOVA followed by an SNK multiple comparison test indicated that within each tissue type the mean TBARS of each group that 
share a superscript were not significantly (p < 0.05) different.
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Multiple regression analyses
Values for the means of SOD, CAT, GPX activities and
TBARS from the tumors of groups of mice killed after two
weeks on each diet with or without DOX treatment and
the mean tumor growth rate of mice fed each diet and
treated with DOX for five weeks were entered into a for-
ward multiple regression analyses. Multiple regression
analyses can address the question: What variable(s)
present in the tumor prior to or after DOX treatment best
correlates with the response of the tumor to DOX treat-
ment? The results of the analyses (Table 4) revealed that
GPX activity in the tumor prior to DOX treatment ex-
plained 78% of the variation in tumor growth rate (the
correlation coefficient (r) between GPX activity in the tu-
mor before DOX treatment and the tumor growth rate fol-
lowing DOX treatment was 0.88). Increased TBARS
following DOX treatment added an additional 19% expla-
nation for the variation in tumor growth rate. Thus, 97%
of the variation in tumor growth rate could be explained
by the diet induced decrease in GPX activity and by in-
creased lipid peroxidation in the tumor following DOX
treatment.
Body weight
The mean body weight change of each group of tumor
bearing mice following consumption of each diet for two
weeks or following DOX treatment for five weeks was de-
termined. Two way ANOVA (Table 5) revealed that addi-
tion of Vitamin E to the diet did not significantly effect
body weight but that mice that consumed FOC prior to
DOX treatment gained significantly more weight than did
mice that consumed CO. Neither fat type nor Vitamin E
supplementation significantly altered the change in body
weight during five weeks of DOX treatment.
Discussion
The results of previous studies [2,5–8] indicated that per-
oxidation of highly polyunsaturated n-3 fatty acids, incor-
porated into cell membranes following their
consumption, was likely to be the primary mechanism for
tumor growth suppression following consumption of fish
oil. However, we recently reported that cellular oxidative
stress, as assayed by the ratio of glutathione peroxidase
(GPX) to superoxide dismutase (SOD) activity, was higher
in the MDA-MB 231 breast cancer xenograft of mice that
were fed 3% w/w FOC with 2% w/w corn oil prior to and
during 5 weeks of DOX treatment [15] than in the breast
Table 4: Summary of forward multiple regression analyses between the measured independent variables: SOD, CAT and GPX activities 
in the tumor and the TBARS in the tumor as measured after two weeks on the diet but before DOX treatment or as measured 24 h 
after a single injection of DOX and the dependent variable, tumor growth rate during 5 weeks of DOC treatment.
Variable entered into equation Parameter estimate Partial R2 (Contribution each 
variable)
Cumulative R2 (Cumulative con-
tribution)
Intercept -17.3
GPX 0.138 0.78 0.78
TBARS after DOX 6.50 0.19 0.97
Table 5: Mean body weight change g/wk  SE (n) due to diet and to DOX treatment in mice bearing an MDA-MB-231 human breast 
cancer xenograft.
Diet type Before DOX treatment Body weight change After DOX treatment Body weight change
5% CO 0.19  0.15 (15) -0.42  0.12 (6)
5% CO + E 0.11  0.11 (17) -0.32  0.08 (8)
3% FOC 0.52  0.06 (23) -0.32  0.08 (6)
3% FOC + E 0.33  0.06 (22) -0.40  0.08 (4)
Results of 2-way ANOVA
Fat Sa NS
Vit. E NS NS
Diet*Vit. E NS NS
a The tumor bearing mice fed FOC gained significantly more body weight than tumor bearing mice fed CO before DOX treatment. There was no 
significant difference in body weight loss due to diet in mice given DOX treatment for five weeks.
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cancer xenografts of mice that were fed 5% corn oil. If di-
etary antioxidants are constant, the antioxidative capacity
of tissues depends on the levels of protective cellular anti-
oxidants [16]. Since endogenous antioxidative enzymes
can be altered by FOC consumption [14], we wondered if
oxidative stress was already increased in the MDA-MB 231
breast cancer xenograft of mice consuming FOC before
the initiation of DOX therapy, thereby increasing the sen-
sitivity of the cancer xenograft to DOX.
The results of this study demonstrate that the implanted
MDA-MB 231 tumors of mice that consumed FOC were
more sensitive to DOX induced growth suppression and
exhibited more oxidative damage than the tumors of mice
that consumed the CO diets. Assay of antioxidant enzyme
activity in the tumors, prior to initiation of DOX therapy,
found that the GPX activity was already less in mice fed
FOC and significantly less in mice fed FOC + vitamin E
than in mice fed either CO diet. Reduced GPX activity
could be due: 1) to reduced transcription of GPX in the tu-
mor 2) to 'using up' of the antioxidative capacity of GPX
or 3) to suppression of GPX activity by hydroperoxide
products of lipid peroxidation [17]. Further investigation
is needed to determine the precise reason but it is evident
that GPX activity was not maintained in tumor cells of
mice that consumed the FOC.
How could reduced GPX activity, associated with con-
sumption of polyunsaturated fatty acids increase the sen-
sitivity to oxidative stress? GPX has been described as the
most important enzyme for stabilizing oxidative reactions
in cells [17]. Under normal conditions, inhibition of GPX
is sufficient to alter cell survival [17] and low GPX activity
is especially lethal under conditions of oxidative stress
such as treatment with antineoplastic agents [17]. PUFAs
can undergo spontaneous and free radical-initiated chain
reactions of lipid peroxidation resulting in the formation
of reactive lipid hydroperoxides. Both GPX and CAT can
neutralize peroxides but GPX has been reported to be
more important than CAT to neutralize lipid hydroperox-
ides [18]. In cells with a high susceptibility for lipid per-
oxidation (i.e. tumor cells of FOC fed mice), adequate
GPX activity is essential to neutralize lipid hydroperox-
ides, breaking the chain reaction of peroxidative damage
and thus reducing the generation of free radicals. In the
current study and in our previous report [15], of the vari-
ables measured, the FOC induced decrease in GPX activity
in the tumor best explained the increased sensitivity of the
tumor to subsequent DOX chemotherapy. GPX was not
decreased in the normal colon or liver indicating that nor-
mal tissues responded to the FOC diet differently than did
the tumor and that normal tissues could maintain GPX ac-
tivity.
Body weight and tumor growth rate
It has been reported that omega 3 fatty acids can decrease
tumor cachexia [19–21]. It is important to note that tu-
mor bearing mice that received only 3% FOC in their diet
gained more weight prior to initiation of DOX therapy
than mice that did not receive FOC. At the initiation of
DOX therapy, the tumors of FOC fed mice were slightly,
(but not significantly) smaller than the tumors of the CO
fed mice and at the end of the study the tumors of FOC fed
mice were significantly smaller than the tumors of CO fed
mice, thus the higher weight gain has to be body weight,
not tumor weight. The significantly higher body weight
gain is likely due to reduced tumor related cachexia.
CO and FOC fed groups did not lose different amounts of
body weight during DOX treatment. This fact and the
maintenance of antioxidant enzyme production in colon
and liver are indications that the toxicity of DOX to nor-
mal host tissues was not increased by the FOC diet.
The tumor growth curves (Figure 1) illustrate the signifi-
cant enhancement of the efficacy of DOX against MDA-
MB 231 human breast cancer xenografts when FOC was
incorporated in the diet. The tumor growth rate of mice
consuming either FOC diet was significantly less than the
tumor growth rate of mice consuming either CO diet. It is
interesting that adding vitamin E to the CO diet slightly
increased the mean growth rate of the tumors. Since vita-
min E quenches oxidation and oxidative damage is one of
the mechanisms of action of DOX [13], it would be ex-
pected that addition of vitamin E to the diet of mice bear-
ing tumors with adequate GPX activity, might reduce the
efficacy of DOX against the tumor.
Conclusions
These results indicate that n-3 PUFAs in the diet are incor-
porated in cell membranes, increasing the polyunsatura-
tion of the membrane and increasing the susceptibility for
lipid peroxidation. The inability of cancer cells to main-
tain the activity of GPX in the presence of a diet containing
n-3 PUFAs was related to increased oxidative damage to
membrane lipids and to significant enhancement of the
efficacy of DOX therapy. Tumor bearing mice that con-
sumed n-3 PUFAs gained more weight prior to DOX ther-
apy than mice that did not receive n-3 PUFAs indicating
that tumor induced cachexia was reduced. Clinical trials
are needed to test the use of this non-toxic supplement as
an adjuvant for patients undergoing DOX chemotherapy.
Methods and Materials
Preparation of cells
Cultured MDA-MB 231 cells (American Type Culture Col-
lection, Rockville, MD) were harvested, rinsed then sus-
pended in serum-free M3D base culture medium (INCELL
Corporation, LLC, San Antonio, TX). Cells in suspension
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were counted using a hemocytometer and the cell count
was adjusted to 20  106/ml. The suspension was kept
well mixed during the time of injection. MDA-MB 231
cells (1  106 cells in 0.05 ml of serum free media) were
injected sc between the scapulae of each mouse.
Dietary fatty acids
Corn oil (CO) contains about 50% linoleic acid, 23%
oleic acid, 10% C16 fatty acids and < 1% n-3 PUFAs. The
n-3 ethyl ester concentrate of fish oil (FOC) containing >
65% n-3 ethyl esters, (> 33% EPA, > 22% DHA, 10% other
n-3 fatty acids), was obtained from the Lipro AS, Norway
and was supplied antioxidant-free. This oil is made in ac-
cordance with Good Manufacturing Practice and is ap-
proved as a food additive for humans. The oil is saturated
with nitrogen to prevent oxidation during shipping and
storage.
Animals and diet
This experiment was conducted at the University of Texas
Health Science Center. All animal use and handling was
approved by the UTHSCSA Institutional Animal Care and
Use Committee. Eighty female athymic nu/nu mice (Har-
lan Sprague Dawley Inc. Madison, WI), 3 months old re-
ceived tumor cells. The mice were housed under aseptic
conditions in a temperature (24C) and light-controlled
(12 h/day) room.
The tumor cell bearing mice were fed the AIN-76 semipu-
rified diet from receipt until three weeks after injection of
cells to allow the tumor to become established. Nude
mice bearing growing MDA-MB-231 human breast carci-
noma xenografts were then divided into four dietary
groups (20 mice per group) such that the mean tumor size
was not different between groups. One group received the
standard AIN-76 diet containing 5% CO (the CO diet),
one group received the 5% CO diet supplemented with
2000 IU/kg Vitamin E (the CO+E diet), one group, re-
ceived the AIN-76 diet modified to contain 3% FOC and
2% CO (the FOC diet) and the final group received the
3% FOC and 2% CO supplemented with 2000 IU/kg Vi-
tamin E (the FOC+E diet). Supplemental vitamin E was
added to quench in vivo lipid peroxidation due to the diet.
The diet composition is given in Table 6. Diets were pre-
pared weekly, daily portions were individually packaged
and stored at -20C in sealed containers with nitrogen gas
atmosphere to prevent lipid peroxidation. Mice were fed
fresh food each day and food remaining in the cage was
discarded.
Tumor and body weight measurements
Lengths and widths of tumors and body weights were
measured three times weekly. Tumor sizes were calculated
using the formula for the volume of a prolate spheroid: V
= 4/3 * 3.14 * L/2 * W/2 * D/2. The width measurement
was used as the depth of the tumor. The body weight
change before DOX treatment was determined by sub-
tracting the mouse body weight on the day of the diet
change from the body weight on the day of the first DOX
treatment, thus this represents body weight change due to
effects of the growing tumor and of the diet. The body
weight change after DOX treatment was determined by
subtracting the mouse body weight on the day of the first
DOX injection from the mouse body weight on the day of
killing and represents body weight change due to diet, to
the growing tumor and to DOX therapy.
Table 6: The energy content of the diet, calculated at 16.7 J/g for protein and carbohydrate, 37.7 J/g for fat is 16.3 J/g. Diet components 
and chemicals – Purified high nitrogen casein, pure corn starch, Alphacel (non-nutritive bulk cellulose), AIN-76 vitamin mixture, AIN-
76 mineral mixture and choline bitartrate (99% pure) was obtained from ICN Nutritional Biochemicals, Cleveland, OH. Imperial brand 
(Sugarland, TX) extra fine pure cane sugar and 100% pure corn oil (Wesson) were purchased locally. D.L. methionine was purchased 
from Sigma, St. Louis, MO. Corn oil (CO) contains about 50% linoleic acid, 23% oleic acid, 10% C16 fatty acids and < 1% n-3 PUFAs. The 
n-3 ethyl ester concentrate of fish oil (FOC) contains >65% n-3 ethyl esters, (>33% EPA, >22% DHA, 10% other n-3 fatty acids), was sup-
plied antioxidant free by Lipromega AS, Norway.
Composition of the diet
Ingredient g/100 g
Total fat 5.0
Sugar 50.0
Casein 20.0
Cornstarch 15.0
AIN-76 vitamin mix 1.0
AIN-76 mineral mix 3.5
Choline bitartrate 0.2
DL-methionine 0.3
Fiber 5.0
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Doxorubicin therapy
After two weeks of consumption of the diets, five tumor
bearing mice from each dietary group were killed for assay
of the effects of the diet on the tumor and normal tissues
of the mice. DOX therapy (5 mg/kg body weight each 4
days, i.v. in a lateral tail vein) was initiated on the remain-
ing mice of each group. Five tumor bearing mice from
each group were killed 24 h after one dose of DOX for de-
termination of the acute effects of DOX on the sensitized
tumors and normal tissues. After two weeks of DOX treat-
ment, mice were losing excess weight at the given schedule
of DOX treatment so the spacing of injections was in-
creased to each seven days for the next three weeks and
mouse weight stabilized. The remainder of the mice (10
per diet group) received DOX treatment for a total of five
weeks to allow time to generate tumor growth curves and
to determine the long term effects of FOC consumption
and/or DOX treatment. Thus if day 0 was the day of the
first injection, mice received DOX injections on days 0, 4,
8, 12, 19, 26, and 33 and were sacrificed on day 1 or on
day 34.
Necropsy and tissue processing
Mice were deeply anesthetized using a ketamine/rompun
solution prepared by the UTHSCSA veterinarian. The tu-
mor, liver and large intestines were removed at necropsy.
Portions of each tissue were placed individually in a la-
beled vial and flash frozen in liquid nitrogen. At a later
date, frozen livers, colon or tumor were thawed and ho-
mogenized individually at 4C in 280 mM mannitol with
10 mM HEPES buffer with 0.01% BHT using a Polytron
homogenizer. The homogenate was divided into aliquots
and frozen at -70C until subsequent analyses.
Products of lipid peroxidation in tumor, liver, and colon
The total protein content of an aliquot of each tissue ho-
mogenate was analyzed by the method of Bradford [22]
using the Bio-Rad protein assay (micro-method). The
thiobarbituric acid reactive substances (TBARS) assay was
used to estimate lipid peroxidation in the homogenate.
Malondialdehyde and other products of lipid peroxida-
tion can be estimated spectrophotometrically at 535 nm
after reaction with thiobarbituric acid to obtain an index
for lipid peroxidation [23]. The absorbance values ob-
tained were compared against a standard curve of known
concentrations of malondialdehyde and normalized to
the protein content of the specimen. The results were re-
ported as nmol of TBARS per mg of protein.
Gas chromatography (GC)
The incorporation of fatty acids into the mitochondria
and microsomes of colon, liver and tumor was deter-
mined in mice which consumed each diet. An aliquot of
each whole tissue homogenate was fractioned into mito-
chondrial and microsomal fractions by successive centrif-
ugation [600  g for 10 min (remove large debris), 15,000
 g for 5 min (mitochondrial fraction), then 100,000  g
for 1 h (microsomal fraction)] for assay of lipid composi-
tion. Chloroform:methanol was used for lipid extraction
of each fraction; lipids were esterified in acetyl chloride-
methanol as described [24]. Gas chromatography was
done using a Hewlett Packard 5890 Series 11 Gas Chro-
matograph (Palo Alto, CA) and conditions of: oven @
170C initial, 5/min gradient to 220C final temperature,
injector temperature @ 225C, flame-ionization detector
@ 250C, helium carrier gas @ 400 Kpa. Fatty acid methyl
ester standards (Nu-Chek-Prep, Elysian, MN) were used
for peak identification. The fatty acid methyl esters were
reported as the percent of the total methylated fatty acids
(area under the curve).
Enzyme assays
Catalase (CAT) activity in the tissue homogenates was as-
sayed using a microplate adaptation of the method of
Aebi [25]. In this method, the decomposition of H2O2
due to CAT activity was assayed by the decrease in the ab-
sorbance of H2O2 at 240 nm.
Superoxide dismutase (SOD) activity of tissue homoge-
nates was determined using a microplate adaptation of
the ferricytochrome C reduction assay of Flohé and Ötting
[26]. In this method, the reduction of cytochrome C by su-
peroxide radicals is monitored at 550 nm utilizing the
xanthine-xanthine oxidase system as the source for super-
oxide.
Glutathione peroxidase (GPX) activity of tissue homoge-
nates was determined using a microplate adaptation of
the glutathione peroxidase assay of Paglia and Valentine
[27]. This method follows the decrease in absorbance at
340 nm as NADPH is converted to NADP.
Statistical analyses
SAS computer software was used for statistical analyses.
Tests for normality (basic statistics) were used on each
data set. Two-way and one-way analyses of variance
(ANOVA) followed by Student-Newman-Keuls (SNK)
multiple range tests, as appropriate, were used to deter-
mine statistically significant (p < 0.05) differences in
measured parameters due to the diet or to the chemother-
apy. PRISM™ (GraphPad Software, San Diego, CA) was
used to generate an ANOVA to test for differences between
linear regression curves of tumor growth. Multiple linear
regression analysis with forward selection was used to test
for correlations in the data between the independent var-
iables: SOD, CAT and GPX activity in the tumor prior to
DOX therapy, and TBARS prior to or after DOX therapy
and the dependent variable, the tumor growth rate follow-
ing DOX treatment.
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